BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niu ZS, Niu XJ, Wang WH. Genetic alterations in hepatocellular carcinoma: An update. World J Gastroenterol 2016; 22(41): 9069-9095 [PMID: 27895396 DOI: 10.3748/wjg.v22.i41.9069] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 79] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors? Crit Rev Oncol Hematol 2022;:103597. [PMID: 35033663 DOI: 10.1016/j.critrevonc.2022.103597] [Reference Citation Analysis]
3 Shioi Y, Osakabe M, Yanagawa N, Nitta H, Sasaki A, Sugai T. Analysis of somatic copy number alterations in biliary tract carcinoma using a single nucleotide polymorphism array. Future Sci OA 2022;8:FSO766. [PMID: 34900340 DOI: 10.2144/fsoa-2021-0057] [Reference Citation Analysis]
4 Lei T, Zhu X, Zhu K, Jia F, Li S. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway. Cancer Biol Ther 2019;20:1007-16. [PMID: 30929558 DOI: 10.1080/15384047.2019.1595276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
5 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
6 Jin YJ, Byun S, Han S, Chamberlin J, Kim D, Kim MJ, Lee Y. Differential alternative splicing regulation among hepatocellular carcinoma with different risk factors. BMC Med Genomics 2019;12:175. [PMID: 31856847 DOI: 10.1186/s12920-019-0635-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Chen X, Liao L, Li Y, Huang H, Huang Q, Deng S. Screening and Functional Prediction of Key Candidate Genes in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Biomed Res Int 2020;2020:7653506. [PMID: 33102593 DOI: 10.1155/2020/7653506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Koenig AB, Barajas JM, Guerrero MJ, Ghoshal K. A Comprehensive Analysis of Argonaute-CLIP Data Identifies Novel, Conserved and Species-Specific Targets of miR-21 in Human Liver and Hepatocellular Carcinoma. Int J Mol Sci 2018;19:E851. [PMID: 29538313 DOI: 10.3390/ijms19030851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
10 Carlessi R, Köhn-gaone J, Olynyk JK, Tirnitz-parker JEE; School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, Fiona Stanley and Fremantle Hospitals, Fremantle and Murdoch, WA, Australia, School of Health and Medical Sciences, Edith Cowan University, Joondalup, WA, Australia, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, The University of Western Australia, Crawley WA, Australia. Mouse Models of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 69-94. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cheng H, Pan Y, Yao Y, Zhu Z, Chen J, Sun X, Qiu Y, Ding Y. Expression and significance of caveolin-1 in hepatitis B virus-associated hepatocellular carcinoma. Exp Ther Med 2017;14:4356-62. [PMID: 29067114 DOI: 10.3892/etm.2017.5038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Kong F, Kong D, Yang X, Yuan D, Zhang N, Hua X, You H, Zheng K, Tang R. Integrative analysis of highly mutated genes in hepatitis B virus-related hepatic carcinoma. Cancer Med 2020;9:2462-79. [PMID: 32017470 DOI: 10.1002/cam4.2903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Huang S, Zhou D, Li YX, Ming ZY, Li KZ, Wu GB, Chen C, Zhao YN. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3. J Cell Physiol 2019;234:3500-14. [PMID: 30370582 DOI: 10.1002/jcp.26863] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
14 Hu G, Gao F, Wang G, Fang Y, Guo Y, Zhou J, Gu Y, Zhang C, Gao N, Wen Q, Qiao H. Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker. J Transl Med 2021;19:359. [PMID: 34412629 DOI: 10.1186/s12967-021-03038-3] [Reference Citation Analysis]
15 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Reference Citation Analysis]
16 Zhang L, Huang Y, Zhu Y, Yu Z, Shao M, Luo Y. Identification and Characterization of Cadmium-Related Genes in Liver Carcinoma. Biol Trace Elem Res 2018;182:238-47. [DOI: 10.1007/s12011-017-1106-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
17 Zhang H, Zhang Z, Gao L, Qiao Z, Yu M, Yu B, Yang T. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. Onco Targets Ther 2019;12:2149-57. [PMID: 30962696 DOI: 10.2147/OTT.S197326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 5.7] [Reference Citation Analysis]
18 Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) 2017;9:E127. [PMID: 28930164 DOI: 10.3390/cancers9090127] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
19 Karakülah G, Yandim C. Identification of differentially expressed genomic repeats in primary hepatocellular carcinoma and their potential links to biological processes and survival. Turk J Biol 2021;45:599-612. [PMID: 34803457 DOI: 10.3906/biy-2104-13] [Reference Citation Analysis]
20 Du S, Liao S, Liu S, Xin Y. TM6SF2 E167K Variant Overexpression Promotes Expression of Inflammatory Cytokines in the HCC Cell Line HEPA 1-6. J Clin Transl Hepatol 2019;7:27-31. [PMID: 30944816 DOI: 10.14218/JCTH.2018.00055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Cano L, Bertani S, Island ML, Cerapio JP, Ruiz E, Pineau P, Monbet V, Boudjema K, Taxa L, Casavilca-Zambrano S, Ropert M, Turlin B, Loréal O. Metallomic profile in non-cirrhotic hepatocellular carcinoma supports a phenomenon of metal metabolism adaptation in tumor cells. Sci Rep 2021;11:14195. [PMID: 34244548 DOI: 10.1038/s41598-021-93369-4] [Reference Citation Analysis]
22 Mangoud NOM, Ali SA, El Kassas M, Soror SH. Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals. IUBMB Life 2021;73:474-82. [PMID: 33347699 DOI: 10.1002/iub.2444] [Reference Citation Analysis]
23 Xiong Y, Yang G, Wang K, Riaz M, Xu J, Lv Z, Zhou H, Li Q, Li W, Sun J, Tao T, Li J. Genome-Wide Transcriptional Analysis Reveals Alternative Splicing Event Profiles in Hepatocellular Carcinoma and Their Prognostic Significance. Front Genet 2020;11:879. [PMID: 32849842 DOI: 10.3389/fgene.2020.00879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 da Silveira MB, Pansa CC, Malaspina O, Moraes KCM. The functional activity of the miR-1914-5p in lipid metabolism of the hepatocarcinoma cell line HepG2: a potential molecular tool for controlling hepatic cellular migration. Mol Biol Rep 2021;48:3463-74. [PMID: 33907947 DOI: 10.1007/s11033-021-06364-3] [Reference Citation Analysis]
25 Xie DY, Fan HK, Ren ZG, Fan J, Gao Q. Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications. Clin Transl Gastroenterol 2019;10:e00006. [PMID: 30829920 DOI: 10.14309/ctg.0000000000000006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
26 Saksouk N, Hajdari S, Perez Y, Pratlong M, Barrachina C, Graber C, Grégoire D, Zavoriti A, Sarrazin A, Pirot N, Noël JY, Khellaf L, Fabbrizio E, Julien E, Cammas FM. The mouse HP1 proteins are essential for preventing liver tumorigenesis. Oncogene 2020;39:2676-91. [PMID: 32020053 DOI: 10.1038/s41388-020-1177-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
27 Morshedi K, Borran S, Ebrahimi MS, Masoud Khooy MJ, Seyedi ZS, Amiri A, Abbasi-Kolli M, Fallah M, Khan H, Sahebkar A, Mirzaei H. Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review. Phytother Res 2021. [PMID: 34173992 DOI: 10.1002/ptr.7119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Azer SA. MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options? J Clin Med 2018;7:E64. [PMID: 29584707 DOI: 10.3390/jcm7040064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
29 Kim SH, Wang WH, Wang JP, Hsieh CH, Fang K. Teroxirone suppresses growth and motility of human hepatocellular carcinoma cells. Biomed Pharmacother 2018;99:997-1008. [PMID: 29653488 DOI: 10.1016/j.biopha.2018.01.157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
30 Yu MC, Lee CW, Lee YS, Lian JH, Tsai CL, Liu YP, Wu CH, Tsai CN. Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data. World J Gastroenterol 2017; 23(44): 7818-7829 [PMID: 29209123 DOI: 10.3748/wjg.v23.i44.7818] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
31 Lin H, Zhang R, Wu W, Lei L. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma. Cancer Genet 2020;245:27-34. [PMID: 32559715 DOI: 10.1016/j.cancergen.2020.04.076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Liu X, Baecker A, Wu M, Zhou JY, Yang J, Han RQ, Wang PH, Jin ZY, Liu AM, Gu X, Zhang XF, Wang XS, Su M, Hu X, Sun Z, Li G, Fu A, Jung SY, Mu L, He N, Li L, Zhao JK, Zhang ZF. Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population. Liver Int. 2019;39:1490-1503. [PMID: 31228882 DOI: 10.1111/liv.14182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
33 Arvanitakis K, Mitroulis I, Germanidis G. Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. Cancers (Basel) 2021;13:2899. [PMID: 34200529 DOI: 10.3390/cancers13122899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Shen JD, Fu SZ, Ju LL, Wang YF, Dai F, Liu ZX, Ji HZ, Shao JG, Bian ZL. High expression of ubiquitin-conjugating enzyme E2A predicts poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;15:7362-8. [PMID: 29725449 DOI: 10.3892/ol.2018.8189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Liu Y, Liu W, Huang J, Lai W, Leng F, Hu C, Zhang Q, Zhou M, Tang Q, Sheng F, Li G, Zhang R. Cu 2-x Se nanoparticles enhance the anticancer activity of oxaliplatin by inhibiting autophagic degradation. Nanomedicine 2019;14:1307-21. [DOI: 10.2217/nnm-2018-0284] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
36 Kim HS, Yoon JS, Jeon Y, Park EJ, Lee JK, Chen S, Lee H, Park JY, Go H, Lee CW. Ssu72-HNF4α signaling axis classify the transition from steatohepatitis to hepatocellular carcinoma. Cell Death Differ 2021. [PMID: 34616001 DOI: 10.1038/s41418-021-00877-x] [Reference Citation Analysis]
37 Leung IC, Chong CC, Cheung TT, Yeung PC, Ng KK, Lai PB, Chan SL, Chan AW, Tang PM, Cheung ST. Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. J Cell Mol Med 2020;24:10705-13. [PMID: 32783366 DOI: 10.1111/jcmm.15691] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Lin Y, Yao Y, Wang Y, Wang L, Cui H. PD-L1 and Immune Infiltration of m6A RNA Methylation Regulators and Its miRNA Regulators in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:5516100. [PMID: 34055974 DOI: 10.1155/2021/5516100] [Reference Citation Analysis]
39 Zhang Z, Zhu J, Huang Y, Li W, Cheng H. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway. Diagn Pathol 2018;13:85. [PMID: 30390677 DOI: 10.1186/s13000-018-0763-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
40 Sivasudhan E, Blake N, Lu ZL, Meng J, Rong R. Dynamics of m6A RNA Methylome on the Hallmarks of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:642443. [PMID: 33869193 DOI: 10.3389/fcell.2021.642443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Fernandes GDS, Campos D, Ballalai A, Palhares R, da Silva MRA, Palhares DMF, Neto BF, Barros FMDR, Gil RA, Chagas A, Carrilho FJ. Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data. J Gastrointest Cancer 2021;52:952-8. [PMID: 32918274 DOI: 10.1007/s12029-020-00508-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Jimenez M, Arechederra M, Ávila MA, Berasain C. Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability. Transl Gastroenterol Hepatol 2018;3:84. [PMID: 30505971 DOI: 10.21037/tgh.2018.10.11] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
43 D'souza S, Lau KCK, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol 2020; 26(38): 5759-5783 [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
44 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci. 2019;64:1016-1029. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
45 Wu WY, Tao SQ, Wang XN, Lobie PE, Wu ZS. XIAP 3'-untranslated region serves as a competitor for HMGA2 by arresting endogenous let-7a-5p in human hepatocellular carcinoma. Tumour Biol 2017;39:1010428317719578. [PMID: 28691642 DOI: 10.1177/1010428317719578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
46 Quan Y, Yang J, Qin T, Hu Y. Associations between twelve common gene polymorphisms and susceptibility to hepatocellular carcinoma: evidence from a meta-analysis. World J Surg Oncol 2019;17:216. [PMID: 31830994 DOI: 10.1186/s12957-019-1748-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
47 Mohamed AA, Omran D, El-Feky S, Darwish H, Kassas A, Farouk A, Ezzat O, Abdo SM, Zahran FE, El-Demery A, Omran MM. Toll-like receptor 7 mRNA is reduced in hepatitis C-based liver cirrhosis and hepatocellular carcinoma, out-performs alpha-fetoprotein levels, and with age and serum aspartate aminotransferase is a new diagnostic index. Br J Biomed Sci 2021;78:18-22. [PMID: 32573389 DOI: 10.1080/09674845.2020.1778842] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Holstein E, Binder M, Mikulits W. Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics. Int J Mol Sci 2018;19:E4111. [PMID: 30567378 DOI: 10.3390/ijms19124111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
49 Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J. Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(13): 2448-2452 [PMID: 28428725 DOI: 10.3748/wjg.v23.i13.2448] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
50 Xiong H, Zhang Y, Chen S, Ni Z, He J, Li X, Li B, Zhao K, Yang F, Zeng Y, Chen B, He F. Induction of SOCS3 by liver X receptor suppresses the proliferation of hepatocellular carcinoma cells. Oncotarget 2017;8:64083-94. [PMID: 28969053 DOI: 10.18632/oncotarget.19321] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
51 Kunadirek P, Chuaypen N, Jenjaroenpun P, Wongsurawat T, Pinjaroen N, Sirichindakul P, Nookaew I, Tangkijvanich P. Cell-Free DNA Analysis by Whole-Exome Sequencing for Hepatocellular Carcinoma: A Pilot Study in Thailand. Cancers (Basel) 2021;13:2229. [PMID: 34066484 DOI: 10.3390/cancers13092229] [Reference Citation Analysis]
52 Raja A, Haq F. Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications. J Cancer Res Clin Oncol 2021. [PMID: 34623518 DOI: 10.1007/s00432-021-03826-w] [Reference Citation Analysis]
53 Ge Y, Gu P, Wang W, Cao L, Zhang L, Li J, Mu W, Wang H. Benzo[a]pyrene stimulates miR-650 expression to promote the pathogenesis of fatty liver disease and hepatocellular carcinoma via SOCS3/JAK/STAT3 cascades. J Mol Cell Biol 2021:mjab052. [PMID: 34450627 DOI: 10.1093/jmcb/mjab052] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Yousef EH, El-Mesery ME, Habeeb MR, Eissa LA. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma. Tumour Biol 2020;42:1010428320914475. [PMID: 32252611 DOI: 10.1177/1010428320914475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Blidisel A, Marcovici I, Coricovac D, Hut F, Dehelean CA, Cretu OM. Experimental Models of Hepatocellular Carcinoma-A Preclinical Perspective. Cancers (Basel) 2021;13:3651. [PMID: 34359553 DOI: 10.3390/cancers13153651] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Zhang X, Li H, Mao M, Wang X, Zheng J, Yang S. Mitotically-associated long non-coding RNA promotes cancer cell proliferation in hepatocellular carcinoma by downregulating miR-122a. Oncol Lett 2019;18:6237-42. [PMID: 31788100 DOI: 10.3892/ol.2019.10947] [Reference Citation Analysis]
57 Mai Q, Sheng D, Chen C, Gou Q, Chen M, Huang X, Yin H, Chen X, Chen Z. Steroid 5 alpha-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC). Aging (Albany NY) 2020;12:25395-411. [PMID: 33229626 DOI: 10.18632/aging.104142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Kovi RC, Bhusari S, Mav D, Shah RR, Ton TV, Hoenerhoff MJ, Sills RC, Pandiri AR. Genome-wide promoter DNA methylation profiling of hepatocellular carcinomas arising either spontaneously or due to chronic exposure to Ginkgo biloba extract (GBE) in B6C3F1/N mice. Arch Toxicol 2019;93:2219-35. [PMID: 31278416 DOI: 10.1007/s00204-019-02505-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Lu YB, Jiang Q, Yang MY, Zhou JX, Zhang Q. Long noncoding RNA NNT-AS1 promotes hepatocellular carcinoma progression and metastasis through miR-363/CDK6 axis. Oncotarget 2017;8:88804-14. [PMID: 29179477 DOI: 10.18632/oncotarget.21321] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
60 Li Y, Xu A, Jia S, Huang J. Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma. Oncol Lett 2019;17:4222-8. [PMID: 30988804 DOI: 10.3892/ol.2019.10127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
61 Shi G, Liu C, Yang Y, Song L, Liu X, Wang C, Peng Z, Li H, Zhong L. Panx1 promotes invasion-metastasis cascade in hepatocellular carcinoma. J Cancer 2019;10:5681-8. [PMID: 31737105 DOI: 10.7150/jca.32986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
62 Wang Y, Sun H, Xiao Z, Zhang D, Bao X, Wei N. XWL-1-48 exerts antitumor activity via targeting topoisomerase II and enhancing degradation of Mdm2 in human hepatocellular carcinoma. Sci Rep 2017;7:9989. [PMID: 28855652 DOI: 10.1038/s41598-017-10577-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
63 Si T, Huang Z, Jiang Y, Walker-Jacobs A, Gill S, Hegarty R, Hamza M, Khorsandi SE, Jassem W, Heaton N, Ma Y. Expression Levels of Three Key Genes CCNB1, CDC20, and CENPF in HCC Are Associated With Antitumor Immunity. Front Oncol 2021;11:738841. [PMID: 34660300 DOI: 10.3389/fonc.2021.738841] [Reference Citation Analysis]
64 Sato K, Meng F, Francis H, Wu N, Chen L, Kennedy L, Zhou T, Franchitto A, Onori P, Gaudio E, Glaser S, Alpini G. Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies. J Pineal Res 2020;68:e12639. [PMID: 32061110 DOI: 10.1111/jpi.12639] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
65 Subramaniam N, Kannan P, K A, Thiruvengadam D. Hepatoprotective effect of boldine against diethylnitrosamine‐induced hepatocarcinogenesis in wistar rats. J Biochem Mol Toxicol 2019;33. [DOI: 10.1002/jbt.22404] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
66 Wu Z, Long X, Tsang SY, Hu T, Yang JF, Mat WK, Wang H, Xue H. Genomic subtyping of liver cancers with prognostic application. BMC Cancer 2020;20:84. [PMID: 32005109 DOI: 10.1186/s12885-020-6546-8] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Rice A, Del Rio Hernandez A. The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA. Front Oncol 2019;9:952. [PMID: 31608239 DOI: 10.3389/fonc.2019.00952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Gruttadauria S, Barbera F, Conaldi PG, Pagano D, Liotta R, Gringeri E, Miraglia R, Burgio G, Barbara M, Pietrosi G, Cammà C, Di Francesco F. Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection. Cancers (Basel) 2021;13:518. [PMID: 33572904 DOI: 10.3390/cancers13030518] [Reference Citation Analysis]
69 Bian J, Long J, Yang X, Yang X, Xu Y, Lu X, Guan M, Sang X, Zhao H. Construction and validation of a prognostic signature using CNV-driven genes for hepatocellular carcinoma. Ann Transl Med 2021;9:765. [PMID: 34268378 DOI: 10.21037/atm-20-7101] [Reference Citation Analysis]
70 Li BH, Wang Y, Wang CY, Zhao MJ, Deng T, Ren XQ. Up-Regulation of Phosphatase in Regenerating Liver-3 (PRL-3) Contributes to Malignant Progression of Hepatocellular Carcinoma by Activating Phosphatase and Tensin Homolog Deleted on Chromosome Ten (PTEN)/Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway. Med Sci Monit 2018;24:8105-14. [PMID: 30418964 DOI: 10.12659/MSM.913307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
71 Enríquez-Cortina C, Bello-Monroy O, Rosales-Cruz P, Souza V, Miranda RU, Toledo-Pérez R, Luna-López A, Simoni-Nieves A, Hernández-Pando R, Gutiérrez-Ruiz MC, Calvisi DF, Marquardt JU, Bucio L, Gomez-Quiroz LE. Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis. Oncotarget 2017;8:104136-48. [PMID: 29262627 DOI: 10.18632/oncotarget.22024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
72 Murugesan K, Sharaf R, Montesion M, Moore JA, Pao J, Pavlick DC, Frampton GM, Upadhyay VA, Alexander BM, Miller VA, Javle MM, Bekaii Saab TS, Albacker LA, Ross JS, Ali SM. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol 2021;5:PO. [PMID: 34476330 DOI: 10.1200/PO.20.00397] [Reference Citation Analysis]
73 Wang J, Huang R, Huang Y, Chen Y, Chen F. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis. Adv Ther 2021;38:3342-61. [PMID: 34014550 DOI: 10.1007/s12325-021-01762-2] [Reference Citation Analysis]
74 Duan YM, Jin Y, Guo ML, Duan LX, Wang JG. Differentially expressed genes of HepG2 cells treated with gecko polypeptide mixture. J Cancer 2018;9:2723-33. [PMID: 30087713 DOI: 10.7150/jca.26339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
75 Chen D, Li X, Li H, Wang K, Tian X. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. J Oncol 2022;2022:5313149. [PMID: 35027925 DOI: 10.1155/2022/5313149] [Reference Citation Analysis]
76 Sequera C, Manzano S, Guerrero C, Porras A. How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma. Hepat Oncol 2018;5:HEP05. [PMID: 30302196 DOI: 10.2217/hep-2017-0026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
77 Kaur H, Bhalla S, Raghava GPS. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles. PLoS One 2019;14:e0221476. [PMID: 31490960 DOI: 10.1371/journal.pone.0221476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
78 Zeng Y, Shen Z, Gu W, Wu M. Inhibition of hepatocellular carcinoma tumorigenesis by curcumin may be associated with CDKN1A and CTGF. Gene 2018;651:183-93. [PMID: 29408622 DOI: 10.1016/j.gene.2018.01.083] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
79 Fan JC, Zeng F, Le YG, Xin L. LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR-24-3p. J Cell Biochem 2018;119:6391-7. [PMID: 29091305 DOI: 10.1002/jcb.26479] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
80 Eferl R, Trauner M. Chromosomal instability in HCC: a key function for checkpoint kinase 2. Gut 2018;67:204-5. [PMID: 28476916 DOI: 10.1136/gutjnl-2017-314101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
81 He L, Fan X, Li Y, Chen M, Cui B, Chen G, Dai Y, Zhou D, Hu X, Lin H. Overexpression of zinc finger protein 384 (ZNF 384), a poor prognostic predictor, promotes cell growth by upregulating the expression of Cyclin D1 in Hepatocellular carcinoma. Cell Death Dis 2019;10:444. [PMID: 31168049 DOI: 10.1038/s41419-019-1681-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
82 Yu Q, Yang X, Duan W, Li C, Luo Y, Lu S. miRNA-346 promotes proliferation, migration and invasion in liver cancer. Oncol Lett 2017;14:3255-60. [PMID: 28927074 DOI: 10.3892/ol.2017.6561] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
83 Li L, Zhou YF, Li YL, Wang LL, Arai H, Xu Y. In vitro and in vivo antioxidative and hepatoprotective activity of aqueous extract of Cortex Dictamni. World J Gastroenterol 2017; 23(16): 2912-2927 [PMID: 28522909 DOI: 10.3748/wjg.v23.i16.2912] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
84 Niu Y, Liu F, Wang X, Chang Y, Song Y, Chu H, Bao S, Chen C. miR-183-5p Promotes HCC Migration/Invasion via Increasing Aerobic Glycolysis. Onco Targets Ther 2021;14:3649-58. [PMID: 34113130 DOI: 10.2147/OTT.S304117] [Reference Citation Analysis]